MedTrace Logo

Isotretinoin Versus Excimer Light an Adjuvant in Treating Onychomycosis

NCT06485505 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-04-23

No results posted yet for this study

Summary

3 groups of patients with onychomycosis will be recruited. Group A will receive itraconazole alone. Group B will receive itraconazole + low dose isotretinoin and group C will be treated with itraconazole + excimer light sessions.

Conditions

  • Onychomycosis

Interventions

DRUG

ISOtretinoin 10 MG

Low dose isotretinoin as an adjuvant for itraconazole in treating onychomycosis

DEVICE

excimer light

excimer light as an adjuvant for itraconazole in treating onychomycosis

DRUG

Itraconazole 200 mg

Itraconazole alone

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-12
Primary Completion
2026-07-31
Completion
2026-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06485505 on ClinicalTrials.gov